• Has Group 3.1 pulmonary hypertension chronic obstructive pulmonary disease (PH-COPD) as defined by the Clinical Classification of Pulmonary Hypertension.

• Has a right heart catheterization (RHC) at screening or historical RHC within 12 months before screening that meets hemodynamic criteria.

• Has a physician diagnosis of obstructive lung disease on pulmonary function testing (PFT) performed at screening.

• Has a WHO Functional Class assessment of Class II to IV.

• If on supplemental oxygen, the regimen must be stable.

• Has stable and optimized chronic, baseline COPD-specific therapy.

• If on PDE5 inhibitor, has stable concomitant use (initiated at least 3 months prior to randomization and no change in drug or dosage for at least 3 months prior to randomization) and changes to PDE5 inhibitor dosing is not anticipated during the 24 week Base Period.

• If on antihypertensives and/or a diuretic regimen has stable concomitant use.

• If on anticoagulants has stable concomitant use.

• Is of any sex/gender from 40 to 85 years of age inclusive.

• Female is not pregnant or breastfeeding, and is not of childbearing potential or uses acceptable contraceptive method or abstains from sexual intercourse, or has a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention, or whose history and sexual activity has been reviewed by the investigator.